Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking ...

More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

US researchers behind the new analysis said they hoped the findings would help patients weigh up the potential benefits of ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...

In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...